Gain Therapeutics Advances Parkinson’s Drug Rexaceract Toward Phase 2 Trials — Gain Therapeutics, Inc.

Event summary

Gain Therapeutics' Phase 1b study of rexaceract shows promising biomarker and clinical data, with 81% reduction in GluSph levels after 90 days.
Independent Data Monitoring Committee recommends continuation of the Phase 1b extension study without modification.
Phase 2 trial for rexaceract expected to begin in Q3 2026, enrolling participants across the U.S., Australia, and Europe.
Company promotes Joanne Taylor to Chief Scientific Officer and Terenzio Ignoni to Chief Operating Officer.

The big picture

Gain Therapeutics is positioning itself as a leader in allosteric small molecule therapies for neurodegenerative diseases. The advancement of rexaceract into Phase 2 trials marks a critical step in validating its approach to treating Parkinson’s disease, potentially offering a first-in-class therapy that addresses the underlying mechanisms of the condition. The company’s strategic focus on biomarker-driven development and collaborations with key foundations underscores its commitment to transforming the treatment landscape for neurodegenerative disorders.

What we're watching

Clinical Efficacy: Whether the observed biomarker and clinical benefits of rexaceract will translate into long-term disease modification in Parkinson’s patients.
Regulatory Pathway: The pace at which Gain Therapeutics can advance rexaceract through Phase 2 trials and secure further regulatory milestones.
Pipeline Expansion: How GT-04686, the second product candidate, will progress toward clinical development and potential therapeutic indications beyond Parkinson’s disease.